For many expectant parents, the question of whether it is safe to take common pain relievers during pregnancy carries a lot of emotional weight. Anxiety around every pill, every symptom, and every choice can be intense, especially when headlines raise alarms about long-term risks. A major new scientific review offers important reassurance. According to researchers at City St George’s, University of London, using acetaminophen in pregnancy, often known by the brand name Tylenol, is not associated with an increased risk of autism, ADHD, or intellectual disability in children. This conclusion comes from what is described as the most comprehensive assessment to date of prenatal paracetamol exposure and child neurodevelopment.

The review, published on January 16 in The Lancet Obstetrics, Gynaecology & Women’s Health, focused specifically on whether pregnancy Tylenol use could affect child brain development. Public concern had been rekindled in September 2025 when claims surfaced that acetaminophen use during pregnancy might disrupt fetal brain growth and heighten the likelihood of autism spectrum disorder. These claims built on earlier observational studies that reported small statistical associations between prenatal acetaminophen and later autism diagnoses.

Those earlier studies, however, had significant methodological limitations. Many relied on incomplete or less precise data. Some did not adequately account for important factors such as family history of neurodevelopmental conditions or genetic predisposition. Others did not fully adjust for underlying maternal health issues, including fever, infection, or pain, which themselves may influence developmental outcomes. As a result, it was difficult to know whether any observed risk was related to the medication or to the reason the medication had been taken in the first place.

To address these gaps, the research team carried out a systematic review and meta-analysis, carefully pooling and reanalyzing data from 43 previously published studies. Their goal was to test the hypothesis that acetaminophen use in pregnancy might contribute to autism, ADHD, or intellectual disability. What stands out in this new work is not only the number of studies included but the emphasis on higher quality research designs, particularly those that could better separate the effects of acetaminophen from other confounding factors.

Among the most powerful of these designs are sibling comparison studies. In such studies, researchers look at families in which one child was exposed to acetaminophen in utero and a sibling was not. Because siblings share much of the same genetic background and grow up in the same household environment, comparing them offers a way to control for many underlying influences that can distort risk estimates in more traditional observational work.

The new review examined sibling comparison data for large populations of children. In total, outcomes were analyzed for 262,852 children assessed for autism, 335,255 for ADHD, and 406,681 for intellectual disability. Within these sizable groups, researchers looked for meaningful differences in risk between exposed and unexposed siblings. According to the reported findings, there was no evidence that prenatal acetaminophen use increased the likelihood of any of these conditions once shared genetic and environmental factors were taken into account.

This pattern held not only across sibling designs but also when the team restricted their analyses to the highest quality studies overall. Each of the 43 included studies was evaluated using the Quality In Prognosis Studies tool, known as QUIPS, which assesses how well a study is designed and how likely it is to be biased. Even when the meta-analysis was narrowed to those rated at low risk of bias, the absence of a link between pregnancy acetaminophen and child autism, ADHD, or intellectual disability remained consistent. The same reassuring signal appeared in those studies that followed children for more than five years, which is important because many neurodevelopmental conditions are not firmly diagnosed until later childhood.

Professor Asma Khalil, Professor of Obstetrics and Maternal Fetal Medicine at City St George’s and Consultant Obstetrician, led the study and helped clarify why the new results diverge from past alarm. The authors suggest that the previously reported associations are more likely to reflect underlying factors in the mother, such as genetic susceptibility, fever, or the health condition that prompted her to take acetaminophen, rather than a harmful effect of the drug itself. In other words, when the analysis is refined and controlling for family-level and maternal factors is strengthened, the apparent signal of risk disappears.

In clinical practice, acetaminophen remains the first-line medication recommended for pregnant individuals who need relief from pain or to bring down a fever. Alternatives often carry clearer risks during pregnancy, which is why the guidance from major medical organizations has consistently favored acetaminophen when a medication is needed and taken as directed. The findings from this review align with that longstanding advice and help address lingering doubts that some families may still have after reading earlier headlines.

At the same time, the authors are careful to acknowledge the limits of the currently available evidence. There was not enough consistent information across studies to determine whether potential risks vary by trimester of exposure, frequency of use, or the sex of the baby. Many sibling comparison studies did not report detailed dose patterns or timing, so the meta-analysis could not examine very specific use profiles. As with most observational research, some questions remain open for future work.

For pregnant patients, however, the main message is practical and clear. Untreated high fever in pregnancy can be dangerous for both the pregnant person and the fetus, and significant pain can interfere with sleep, nutrition, and general well-being. This new review supports the view that acetaminophen continues to be a reasonable and safe option when medication is necessary, prescribed, or recommended, and is used according to guidance. It does not suggest that everyone should take acetaminophen routinely, but it does indicate that measured, medically advised use is not linked to heightened risks of autism, ADHD, or intellectual disability.

I found it striking that such a large body of evidence, especially including sibling comparison data, arrived at a consistent conclusion. In a topic area where worry is understandable and consequences feel profound, having careful, cumulative analysis matters. For those navigating pregnancy decisions in partnership with their clinicians, this review offers data-backed reassurance that using acetaminophen responsibly remains compatible with supporting healthy child development.

Read more at https://www.sciencedaily.com/releases/2026/01/260118233553.htm